Insmed, Inc. (INSM)
148.94
+4.48
(+3.10%)
USD |
NASDAQ |
Nov 20, 09:48
Insmed Cash from Operations (Quarterly) : -36.46M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -36.46M |
| June 30, 2026 | -88.83M |
| March 31, 2026 | -222.74M |
| December 31, 2025 | -247.60M |
| September 30, 2025 | -219.76M |
| June 30, 2025 | -205.57M |
| March 31, 2025 | -262.09M |
| December 31, 2024 | -195.98M |
| September 30, 2024 | -180.92M |
| June 30, 2024 | -122.95M |
| March 31, 2024 | -184.04M |
| December 31, 2023 | -129.60M |
| September 30, 2023 | -136.33M |
| June 30, 2023 | -122.79M |
| March 31, 2023 | -147.52M |
| December 31, 2022 | -103.15M |
| September 30, 2022 | -89.83M |
| June 30, 2022 | -102.30M |
| March 31, 2022 | -105.16M |
| December 31, 2021 | -84.13M |
| September 30, 2021 | -75.44M |
| June 30, 2021 | -75.44M |
| March 31, 2021 | -128.28M |
| December 31, 2020 | -66.79M |
| September 30, 2020 | -58.67M |
| Date | Value |
|---|---|
| June 30, 2020 | -35.95M |
| March 31, 2020 | -57.94M |
| December 31, 2019 | -44.40M |
| September 30, 2019 | -52.37M |
| June 30, 2019 | -80.03M |
| March 31, 2019 | -73.85M |
| December 31, 2018 | -69.54M |
| September 30, 2018 | -65.49M |
| June 30, 2018 | -54.91M |
| March 31, 2018 | -68.04M |
| December 31, 2017 | -48.22M |
| September 30, 2017 | -38.24M |
| June 30, 2017 | -36.25M |
| March 31, 2017 | -36.91M |
| December 31, 2016 | -57.96M |
| September 30, 2016 | -30.98M |
| June 30, 2016 | -28.24M |
| March 31, 2016 | -29.53M |
| December 31, 2015 | -27.55M |
| September 30, 2015 | -24.03M |
| June 30, 2015 | -24.24M |
| March 31, 2015 | -24.88M |
| December 31, 2014 | -12.93M |
| September 30, 2014 | -20.90M |
| June 30, 2014 | -17.93M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 340.98M |
| Gilead Sciences, Inc. | 5.035B |
| Incyte Corp. | -675.32M |
| Madrigal Pharmaceuticals, Inc. | 120.56M |
| Vertex Pharmaceuticals, Inc. | 643.10M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -135.65M |
| Cash from Financing (Quarterly) | 23.64M |
| Free Cash Flow | -657.58M |
| Free Cash Flow Per Share (Quarterly) | -0.1924 |
| Free Cash Flow to Equity (Quarterly) | -44.57M |
| Free Cash Flow to Firm (Quarterly) | -21.12M |
| Free Cash Flow Yield | -2.01% |